Skip to main content
. Author manuscript; available in PMC: 2013 May 14.
Published in final edited form as: Annu Rev Pathol. 2008;3:399–425. doi: 10.1146/annurev.pathmechdis.3.121806.151434

Table 1. Modulation of chemotherapeutic efficacy by UPR activity.

Agent Mechanism of action UPR Reference(s)
Etoposide Topoisomerase inhibitor Antagonizes (140)
Doxorubicin Topoisomerase inhibitor Antagonizes (140, 144)
Camptothecin Topoisomerase inhibitor Antagonizes (145)
Cisplatin DNA/protein cross-linker Synergizes (146, 147)
Melphalan DNA/protein cross-linker Synergizes (146)
BCNU DNA/protein cross-linker Synergizes (146)
Bortezomib (Velcade) Proteasome inhibitor Inhibits UPR? (136)
Activates PERK (137)
Activates GCN2 (138)
Combretastatin A4 Antivascular Induces GRP78 (148)
Contortrostatin Anti-angiogenesis Induces GRP78 (148)
Imatinib (Gleevec) BCR-Abl kinase inhibitor Induces UPR (149)